Tim Watts, CFO at Shield Therapeutics #STX presenting at our Life Sciences Investor Briefing Watch Now

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price: 1,671.60
Bid: 1,659.20
Ask: 1,660.20
Change: 13.80 (0.83%)
Spread: 1.00 (0.06%)
Open: 1,649.20
High: 1,678.20
Low: 1,646.40
Yest. Close: 1,657.80
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

GlaxoSmithKline Notes Positive Tango And Gemini HIV Study Results

Wed, 24th Jul 2019 17:20

(Alliance News) - GlaxoSmithKline PLC on Wednesday noted positive results from the Gemini and Tango phase three studies of a dolutegravir plus lamivudine in HIV patients.

The results were announced by ViiV Healthcare, a specialist HIV company in which pharma giant Glaxo has a majority share, with Pfizer Inc and Shionogi Ltd also as shareholders.

Gemini 1 and 2 studies of the two-drug regimen showed it was not inferior to a three-drug regimen at week 96 and there were no cases of treatment emergent resistance in patients with virologic failure.

Pedro Cahn, principal investigator for the Gemini study programme, said: "The week 96 data from the Gemini studies demonstrate that the clinical benefits of dolutegravir plus lamivudine we saw at week 48 are sustainable, allowing us to use these two drugs while still getting efficacy non-inferior to that of a dolutegravir-based 3-drug regimen.

"This provides further evidence for the benefits of this dolutegravir-based 2-drug regimen in a treatment-naive population, and enables physicians and people living with HIV to be confident in the durability of this treatment option. These latest findings are important for people living with HIV who will potentially spend decades taking medication to manage their HIV."

The Tango study, meanwhile, assessed patients who were switching from a three-drug regimen containing tenofovir alafenamide fumarate to the two-drug dolutegravir plus lamivudine regimen.

At 48 weeks, the two-drug regimen was found to have similar efficacy to the three-drug regimen in patients who switched.

Kimberley Smith, head of Global Research & Medical Strategy at ViiV Healthcare, said: "With HIV now considered a chronic condition and people living with HIV needing antiretroviral treatments for life, taking fewer medicines over a lifetime has become an important consideration for the community. The Tango study was designed to answer the question, can a 2-drug regimen of dolutegravir/lamivudine maintain viral suppression as well as a TAF-containing regimen. We're delighted that the week 48 results of the study confirm that it can. These data present evidence that a dolutegravir/lamivudine 2-drug regimen is as effective as a TAF-containing, 3-drug regimen for people living with HIV."

Shares in Glaxo closed down 0.4% at 1,653.60 pence on Wednesday.

More News

BROKER RATINGS SUMMARY: Morgan Stanley Raises SSE To Overweight

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:----------FTSE 100----------DEUTSCHE BANK RAISES RENTOKIL INITIAL

10 Sep 19 09:32

Aurora Investment Trust Net Assets Rise But Total Interim Return Lags

(Alliance News) - Aurora Investment Trust PLC on Monday said its net asset value rose in the first six months of the year but total return lagged behind its benchmark index.At June 30, a of

9 Sep 19 12:12

BROKER RATINGS SUMMARY: Deutsche Bank Raises BHP And Cuts Antofagasta

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:----------FTSE 100----------DEUTSCHE BANK RAISES BHP

4 Sep 19 09:32

Tuesday broker round-up

(Sharecast News) - easyJet: Kepler Cheuvreux downgrades to reduce with a target price of 820p.

3 Sep 19 12:59

BROKER RATINGS SUMMARY: Deutsche Bank Starts Taylor Wimpey At Buy

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:----------FTSE 100----------DEUTSCHE BANK INITIATES TAYLOR WIMPEY

3 Sep 19 09:40

LONDON MARKET OPEN: Ferguson-Wolseley Rises; Pound Falls Below USD1.20

(Alliance News) - Stock prices in London opened mixed on Tuesday, with Ferguson the best blue-chip performer after the company decided to split its UK and US operations, while the pound fell below

3 Sep 19 08:49

Monday broker round-up

(Sharecast News) - Beazley: UBS upgrades to buy with a target price of 650p.

2 Sep 19 13:16

Former Glaxo Vice President To Lead C4X Discovery Advisory Network

(Alliance News) - C4X Discovery Holdings PLC on Monday said it is forming a drug discovery advisory network chaired by "renowned industry veteran" Robin Carr.Shares in C4X were up

2 Sep 19 12:02

BROKER RATINGS SUMMARY: Goldman Sachs Says Buy Unilever, Sell M&S

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday afternoon:----------FTSE 100----------GOLDMAN SACHS WITH

2 Sep 19 09:41

BROKER RATINGS SUMMARY: UBS Raises Greggs; Peel Hunt Lifts Chesnara

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday afternoon and Wednesday morning:----------FTSE 100----------KEPLER RAISES

28 Aug 19 09:37

GlaxoSmithKline's Dreamm-2 Multiple Myeloma Trial Results Encouraging

(Alliance News) - GlaxoSmithKline PLC on Friday reported positive headline results from its Dreamm-2 study of belantamab mafodotin in multiple myeloma.The study, which involved 196 patients

23 Aug 19 07:46

GlaxoSmithKline reveals positive results from belantamab mafodotin trial

(Sharecast News) - GlaxoSmithKline announced positive headline results from the pivotal 'DREAMM-2' open-label, randomised study of two doses of belantamab mafodotin on Friday.

23 Aug 19 07:29

Glaxo's ViiV Reports Positive Study Results Of HIV-Treatment Regimen

(Alliance News) - GlaxoSmithKline PLC on Thursday said ViiV Healthcare reported positive headline results from its global phase III ATLAS-2M study.ViiV Healthcare is a specialist HIV owned

22 Aug 19 08:20

GlaxoSmithKline upbeat on latest test results from ViiV Healthcare

(Sharecast News) - GlaxoSmithKline reported on Thursday that its specialist HIV company ViiV Healthcare had announced positive headline results from its phase 3 'ATLAS-2M' study of the investigational, long-acting, injectable, two-drug regimen (2DR) of its cabotegravir and Janssen's rilpivirine for the treatment of HIV.

22 Aug 19 07:29

Glaxo Submits Japanese Application For Daprodustat Anaemia Drug

(Alliance News) - GlaxoSmithKline PLC on Wednesday said it has submitted a new drug application in Japan for anaemia drug daprodustat.The application was submitted to the Japanese Ministry

21 Aug 19 08:38

Login to your account

Don't have an account? Click here to register.